

11.05.2023

11:30 - 12:30	<p><b>Type: Industry Satellite Symposium</b></p> <p><b>Title: AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?</b></p> <p>Chair(s): Sara Hurvitz, United States of America; Miguel Martin, Spain</p>	<b>Hamburg Hall</b>
11:30 - 11:35	<p><b>Welcome and introductions</b></p> <p><u>All Speakers</u>, na, Switzerland</p>	
11:35 - 11:45	<p><b>Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer</b></p> <p><u>All Speakers</u>, na, Switzerland</p>	
11:45 - 11:55	<p><b>Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer</b></p> <p><u>All Speakers</u>, na, Switzerland</p>	
11:55 - 12:05	<p><b>Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer</b></p> <p><u>All Speakers</u>, na, Switzerland</p>	
12:05 - 12:15	<p><b>Shared decision-making in HR-positive, HER2-negative early breast cancer: Enhancing patient-provider communication</b></p> <p><u>All Speakers</u>, na, Switzerland</p>	
12:15 - 12:30	<p><b>Questions and take-home messages</b></p> <p><u>All Speakers</u>, na, Switzerland</p>	

<b>11:30 - 12:30</b>	<p><b>Type: Industry Satellite Symposium</b>  <b>Title: AstraZeneca - HR+ metastatic breast cancer - how do we stay ahead of a dynamic disease?</b>            Chair(s): Javier Cortes, Spain</p>	<b>Munich Hall</b>
11:30 - 11:35	<p><b>Introduction</b>  <u>Javier Cortes</u>, International Breast Cancer Center (IBCC); Pangaea Oncology, Quironsalud Group Madrid &amp; Barcelona, Madrid and Barcelona, Spain</p>	
11:35 - 11:45	<p><b>Reacting to a dynamic disease</b>  <u>Komal Jhaveri</u>, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, United States of America</p>	
11:45 - 11:55	<p><b>Moving ahead of a dynamic disease</b>  <u>François Clément Bidard</u>, Institut Curie, Paris, France</p>	
11:55 - 12:05	<p><b>Gaining momentum with new modalities</b>  <u>Javier Cortes</u>, International Breast Cancer Center (IBCC); Pangaea Oncology, Quironsalud Group Madrid &amp; Barcelona, Madrid and Barcelona, Spain</p>	
12:05 - 12:30	<p><b>Q&amp;A / discussion</b>  <u>To Be Announced</u>, Barcelona, Spain</p>	
<b>11:30 - 12:30</b>	<p><b>Type: Industry Satellite Symposium</b>  <b>Title: Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer</b>            Chair(s): Sherko Kuemmel, Germany</p>	<b>Frankfurt Hall</b>
11:30 - 11:35	<p><b>Welcome and introductions</b>  <u>Sherko Kuemmel</u>, KEM, Evang. Hospital Essen-Mitte, Essen, Germany</p>	
11:35 - 12:00	<p><b>First-line treatment in HR+/HER2- ABC: Patient cases</b>  <u>Sherko Kuemmel</u>, KEM, Evang. Hospital Essen-Mitte, Essen, Germany</p>	
12:00 - 12:20	<p><b>Sequencing following progression after first-line CDK4/6i: Patient cases</b>  <u>Michelino De Laurentiis</u>, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Università degli Studi di Napoli "Federico II", Napoli, Italy</p>	
12:20 - 12:25	<p><b>Closing and key takeaways</b>  <u>To Be Announced</u>, Barcelona, Spain</p>	
12:25 - 12:30	<p><b>Live Q&amp;A</b>  <u>To Be Announced</u>, Barcelona, Spain</p>	

<b>12:30 - 13:00</b>	<b>Type: Break</b> <b>Title: Welcome reception</b>	<b>Exhibition area</b>
<b>13:00 - 13:40</b>	<b>Type: Opening and award lecture</b> <b>Title: Welcome to the ESMO Breast Cancer 2023 and 2023 award lecture</b> Chair(s): Suzette Delaloge, France; Erika Hamilton, United States of America; Sung-Bae Kim, Korea, Republic of	<b>Berlin Hall</b>
13:00 - 13:10	<b>Opening session</b> <u>Suzette Delaloge</u> <sup>1</sup> , <u>Erika Hamilton</u> <sup>2</sup> , <u>Sung-Bae Kim</u> <sup>3</sup> , <sup>1</sup> Institut Gustave Roussy, Villejuif, France, <sup>2</sup> Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America, <sup>3</sup> Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of	
13:10 - 13:15	<b>Introduction to the ESMO Breast Cancer 2023 award lecture</b> <u>Erika Hamilton</u> , Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America	
13:15 - 13:40	<b>Progress through challenging dogma</b> <u>Sara Hurvitz</u> , UCLA Hematology/Oncology Santa Monica, Santa Monica, United States of America	
<b>14:00 - 15:30</b>	<b>Type: Educational session</b> <b>Title: Optimal treatment strategies in early breast cancer</b> Chair(s): Shani Paluch-Shimon, Israel	<b>Berlin Hall</b>
14:00 - 14:20	<b>Optimal systemic therapy choices for HR+/HER2- pre-menopausal patients</b> <u>Nadia Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, Germany	
14:20 - 14:40	<b>Triple-negative breast cancer (TNBC): It's not one size fits all</b> <u>Peter Schmid</u> , Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, United Kingdom	
14:40 - 15:00	<b>Breast conservation and axillary management after neo-adjuvant therapy</b> <u>Oreste Gentilini</u> , IRCCS Ospedale San Raffaele, Milan, Italy	
15:00 - 15:20	<b>Adjuvant radiation: Standards of care in 2023</b> <u>Orit Kaidar-Person</u> , Chaim Sheba Medical Center, Ramat Gan, Israel	
15:20 - 15:30	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	

**14:00 - 15:28**    **Type: Proffered Paper session**    **Hamburg Hall**  
**Title: Proffered Paper session 1**  
 Chair(s): Erika Hamilton, United States of America; Sung-Bae Kim, Korea, Republic of

- 14:00 - 14:12    **1850 - Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): a detailed safety analysis of the randomized, phase 3 DESTINY-Breast04 trial**  
Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America
- 14:12 - 14:24    **1860 - Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC)**  
Tanja Fehm, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- 14:24 - 14:34    **Invited Discussant 1850 and 1860**  
Gustavo Werutsky, Latin American Cooperative Oncology Group, Porto Alegre, Brazil
- 14:34 - 14:44    **Q&A and discussion**  
To Be Announced, Barcelona, Spain
- 14:44 - 14:56    **1870 - Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): subgroup analyses from the Phase 3 CAPitello-291 trial**  
Nicholas Turner, Oncomedica S.A., London, United Kingdom
- 14:56 - 15:08    **1880 - EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2\_ advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy**  
Javier Cortes, International Breast Cancer Center (IBCC); Pangaea Oncology, Quironsalud Group Madrid & Barcelona, Madrid and Barcelona, Spain
- 15:08 - 15:18    **Invited Discussant 1870 and 1880**  
Lisa Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, United States of America
- 15:18 - 15:28    **Q&A and discussion**  
To Be Announced, Barcelona, Spain

<b>14:00 - 15:30</b>	<b>Type: Special symposium</b> <b>Title: Selecting biomarkers to inform neoadjuvant strategies</b> Chair(s): Aleix Prat, Spain; Jee Hyun Kim, Korea, Republic of	<b>Munich Hall</b>
14:00 - 14:20	<b>Gene-expression profiling to guide neoadjuvant treatment in HR+/HER2- breast cancer</b> <u>Aleix Prat</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, Spain	
14:20 - 14:40	<b>Biomarkers beyond PD-L1 to inform neoadjuvant immunotherapies in TNBC</b> <u>Carsten Denkert</u> , UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, Germany	
14:40 - 15:00	<b>At the crossroad of de-escalation vs escalation in HER2 positive breast cancer: Which biomarkers can help in the neoadjuvant setting?</b> <u>Jee Hyun Kim</u> , Seoul National University Bundang Hospital, Seongnam, Korea, Republic of	
15:00 - 15:20	<b>Points to consider in the development of biomarkers in the neoadjuvant setting: Regulatory perspectives</b> <u>Jonas Bergh</u> , Karolinska Institutet - Bioclinicum, Solna, Sweden	
15:20 - 15:30	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	

<b>14:00 - 15:30</b>	<b>Type: Educational session</b> <b>Title: Targeted options for advanced luminal breast cancers</b> Chair(s): Otto Metzger, United States of America	<b>Frankfurt Hall</b>
14:00 - 14:20	<b>Next generation tyrosine kinase inhibitors</b> <u>Ana Mafalda Antunes De Melo E Oliveira</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
14:20 - 14:40	<b>From SERMs to SERDs: Advances and challenges in the development of novel agents (focus on biomarkers)</b> <u>Otto Metzger</u> , Dana Farber Cancer Institute - Longwood Center, Boston, United States of America	
14:40 - 15:00	<b>Luminal HER2 positive vs luminal HER2 negative: Different drivers of endocrine resistance and the role of CDK4/6 inhibitors</b> <u>Luca Malorni</u> , Ospedale di Prato, Azienda USL Toscana Centro, Prato, Italy	
15:00 - 15:20	<b>Digital interactions in the management of targeted treatment</b> <u>Vaz Luis Ines</u> , Institut Gustave Roussy, Villejuif, France	
15:20 - 15:30	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	
<b>15:45 - 16:15</b>	<b>Type: Keynote lecture</b> <b>Title: Keynote lecture - Building evidence using biomarkers and new statistical methods: From prevention to adjuvant treatment of breast cancer</b> Chair(s): Sung-Bae Kim, Korea, Republic of	<b>Berlin Hall</b>
15:45 - 15:50	<b>Introduction by the Chair</b> <u>Sung-Bae Kim</u> , Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of	
15:50 - 16:15	<b>Building evidence using biomarkers and new statistical methods: From prevention to adjuvant treatment of breast cancer</b> <u>Douglas Yee</u> , Minneapolis, United States of America	
<b>16:15 - 16:45</b>	<b>Type: Break</b> <b>Title: Coffee break</b>	<b>Exhibition area</b>

**16:45 - 18:15**    **Type: Educational session**    **Berlin Hall**  
**Title: HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers**  
 Chair(s): Heather McArthur, United States of America

16:45 - 17:05    **Clinical impact of evolving ADC technology**  
Heather McArthur, UTSW - University of Texas Southwestern Medical Center, Dallas, United States of America

17:05 - 17:25    **Current ADC landscape**  
Veronique Dieras, Centre Eugene - Marquis, Rennes, France

17:25 - 17:45    **Emerging toxicities and management strategies**  
Sung-Bae Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of

17:45 - 18:05    **Future directions for ADCs**  
Javier Cortes, International Breast Cancer Center (IBCC); Pangaea Oncology, Quironsalud Group Madrid & Barcelona, Madrid and Barcelona, Spain

18:05 - 18:15    **Q&A and discussion**  
To Be Announced, Barcelona, Spain

**16:45 - 18:15**    **Type: Mini Oral session**    **Munich Hall**  
**Title: Mini Oral session 1**  
 Chair(s): Otto Metzger, United States of America; Marleen Kok, Netherlands

16:45 - 16:50    **93MO - Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)**  
Nadia Harbeck, Ludwig Maximilians University - Grosshadern, Munich, Germany

16:50 - 16:55    **94MO - The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy - DATA trial analysis**  
Senna Lammers, Maastricht University Medical Center (MUMC), Maastricht, Netherlands

16:55 - 17:00    **260MO - Long term patient reported outcomes in premenopausal women with the hormone receptor positive breast cancer from ABCSG 22 Registry**  
Vesna Bjelic-Radisic, Helios University Hospital Wuppertal, Wuppertal, Germany

17:00 - 17:10    **Invited Discussant 93MO, 94MO and 260MO**  
Otto Metzger, Dana Farber Cancer Institute - Longwood Center, Boston, United States of America

17:10 - 17:20    **Q&A and discussion**

To Be Announced, Barcelona, Spain

- 17:20 - 17:25 **190MO - Association of 18-Gene Expression Profile (GEP) With Clinical Outcomes in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated With Pembrolizumab (Pembro) or Chemotherapy (Chemo) in KEYNOTE-119**  
Peter Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, United Kingdom
- 17:25 - 17:30 **191MO - KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs**  
Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America
- 17:30 - 17:35 **1MO - Tumor immune microenvironment in ER-negative vs. ER-low, HER2-neg breast cancer**  
Davide Massa, IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy
- 17:35 - 17:40 **2MO - Expression levels of immune checkpoint markers (IC) in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)**  
Anirudh Pabba, KU Leuven, Leuven, Belgium
- 17:40 - 17:52 **Invited Discussant 190MO, 191MO, 1MO and 2MO**  
Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands
- 17:52 - 18:07 **Q&A and discussion**  
To Be Announced, Barcelona, Spain



<b>16:45 - 18:15</b>	<b>Type: Educational session</b> <b>Title: From familial to theranostic germline genetics in breast cancer</b> Chair(s): Judith Balmana, Spain	<b>Frankfurt Hall</b>
16:45 - 17:05	<b>Current advances in breast cancer risk assessment: Prime time for a personalised approach?</b> <u>Antonis Antoniou</u> , University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom	
17:05 - 17:25	<b>Advances in imaging for early breast cancer detection among high-risk women</b> <u>Macheteld Keupers</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium	
17:25 - 17:45	<b>Fertility issues in women with breast cancer and a germline pathogenic variant</b> <u>Matteo Lambertini</u> , University of Genova - IRCCS Policlinico San Martino Hospital, Genova, Italy	
17:45 - 18:05	<b>Role of germline genetic testing in early breast cancer for therapeutic purposes</b> <u>Soo Chin Lee</u> , National University Cancer Institute, Singapore, Singapore	
18:05 - 18:15	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	
<b>18:30 - 19:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Daiichi Sankyo - Key targets for ADC directed therapy in breast cancer</b> Chair(s): Ian Krop, United States of America	<b>Hamburg Hall</b>
18:30 - 18:35	<b>Introduction</b> <u>Ian Krop</u> , Yale University School of Medicine - Yale Cancer Center, New Haven, United States of America	
18:35 - 18:55	<b>Current targets for ADCs approved in the breast cancer treatment landscape</b> <u>Ian Krop</u> , Yale University School of Medicine - Yale Cancer Center, New Haven, United States of America	
18:55 - 19:15	<b>Investigational ADCs and recently identified target antigens in breast cancer</b> <u>Barbara Pistilli</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
19:15 - 19:30	<b>Live Q&amp;A session</b> <u>To Be Announced</u> , Barcelona, Spain	

<b>18:30 - 19:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: MSD - Perspectives on the treatment of HER2-negative gBRCAm early breast cancer</b> Chair(s): Peter A. Fasching, Germany	<b>Munich Hall</b>
18:30 - 18:35	<b>Introductions</b> <u>Peter A. Fasching</u> , Universitätsklinikum Erlangen, Erlangen, Germany	
18:35 - 18:55	<b>Evolving treatment landscape in HER2-negative gBRCAm patients</b> <u>Karen Gelmon</u> , BC Cancer Agency - Vancouver, Vancouver, Canada	
18:55 - 19:10	<b>Patient case study</b> <u>Rupert Bartsch</u> , Medical University of Vienna, Vienna, Austria	
19:10 - 19:25	<b>Q&amp;A / discussion</b> <u>To Be Announced</u> , Barcelona, Spain	
19:25 - 19:30	<b>Closing</b> <u>Peter A. Fasching</u> , Universitätsklinikum Erlangen, Erlangen, Germany	

<b>18:30 - 19:30</b>	<p><b>Type: Industry Satellite Symposium</b>  <b>Title: Pierre Fabre - Are we improving the odds of surviving cancer? Optimizing adjuvant therapy in HER2+ breast cancer</b>                  Chair(s): Diana Luftner, Germany</p>	<b>Frankfurt Hall</b>
18:30 - 18:35	<p><b>Welcome and introduction</b>  <u>Diana Luftner</u>, MHB - Brandenburg Medical School Theodor Fontane Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, Germany</p>	
18:35 - 18:45	<p><b>Are we taking the right choices? New insights on risk assessment in patients with HER2+ EBC</b>  <u>Christian Jackisch</u>, Sana Klinikum Offenbach GmbH, Offenbach am Main, Germany</p>	
18:45 - 18:55	<p><b>The wise move: Current strategies in high-risk HER2+ EBC</b>  <u>Miguel Martin</u>, Hospital General Universitario Gregorio Marañón, Madrid, Spain</p>	
18:55 - 19:10	<p><b>From data to practice: A clinical case challenge</b>  <u>Christian Jackisch</u>, Sana Klinikum Offenbach GmbH, Offenbach am Main, Germany</p>	
19:10 - 19:25	<p><b>Delivering the continuum of care: Setting each patient up for treatment success</b>  <u>Diana Luftner</u>, MHB - Brandenburg Medical School Theodor Fontane Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, Germany</p>	
19:25 - 19:30	<p><b>Q&amp;A and closing remarks</b>  <u>Diana Luftner</u>, MHB - Brandenburg Medical School Theodor Fontane Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, Germany</p>	

12.05.2023

**08:45 - 10:15** Type: Mini Oral session **Berlin Hall**  
Title: Mini Oral session 2

Chair(s): Peter A. Fasching, Germany; Carmen Criscitiello, Italy; Andrew Tutt, United Kingdom

- 08:45 - 08:50 **193MO - Development of a Deep Learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC)**  
Laura Vuduc, CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, France
- 08:50 - 08:55 **3MO - HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial**  
Fara Brasó-Maristany, IDIBAPS - Fundació de Recerca Clinic Barcelona, Barcelona, Spain
- 08:55 - 09:00 **192MO - DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)**  
David Cameron, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom
- 09:00 - 09:10 **Invited Discussant 193MO, 3MO and 192MO**  
Peter A. Fasching, Universitätsklinikum Erlangen, Erlangen, Germany
- 09:10 - 09:18 **Q&A and discussion**  
To Be Announced, Barcelona, Spain
- 09:18 - 09:23 **125MO - Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)**  
Kenichi Inoue, Saitama Prefectural Cancer Center, Ina, Japan
- 09:23 - 09:28 **126MO - HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies**  
Adrienne Waks, Dana Farber Cancer Institute, Boston, United States of America
- 09:28 - 09:36 **Invited Discussant 125MO and 126MO**  
Carmen Criscitiello, Istituto Europeo di Oncologia, Milan, Italy
- 09:36 - 09:42 **Q&A and discussion**  
To Be Announced, Barcelona, Spain
- 09:42 - 09:47 **171MO - Inflammatory profiling of individuals with germline TP53 mutations (gTP53m) and its relationship to subsequent cancer development**

Tarek Ben Ahmed, Gustave Roussy - Cancer Campus, Villejuif, France

09:47 - 09:52 **95MO - Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE) for early-stage triple-negative breast cancer (eTNBC) with an incomplete response to neoadjuvant therapy (NAT)**

Tanya Gupta, Stanford Cancer Center Palo Alto, Palo Alto, United States of America

09:52 - 09:57 **4MO - Homologous recombination (HR) status of platinum responsive advanced triple negative breast cancers (aTNBC) treated with olaparib as maintenance therapy**

Tira Tan, NCCS - National Cancer Centre Singapore, Singapore, Singapore

09:57 - 10:07 **Invited Discussant 171MO, 95MO and 3MO**

Andrew Tutt, ICR - Institute of Cancer Research, London, United Kingdom

10:07 - 10:15 **Q&A and discussion**

To Be Announced, Barcelona, Spain

08:45 - 10:15	<b>Type: Educational session</b> <b>Title: Optimal sequencing in advanced luminal breast cancer</b> Chair(s): Monica Arnedos, France; Gustavo Werutsky, Brazil	<b>Munich Hall</b>
---------------	--	--------------------

08:45 - 09:10 **Recent progresses on the treatment of luminal metastatic breast cancer with CDK 4/6 inhibitors**

Gustavo Werutsky, Latin American Cooperative Oncology Group, Porto Alegre, Brazil

09:10 - 09:35 **Emerging data on oral selective estrogen receptor degraders**

Sara Hurvitz, UCLA Hematology/Oncology Santa Monica, Santa Monica, United States of America

09:35 - 10:00 **New insights on endocrine therapy resistance in luminal metastatic breast cancer**

Monica Arnedos, Institute Bergonié, Bordeaux, France

10:00 - 10:15 **Q&A and discussion**

To Be Announced, Barcelona, Spain

**08:45 - 10:15** **Type: Young Oncologists session** **Frankfurt Hall**  
**Title: YO Clinical case discussion**  
Chair(s): Kevin Punie, Belgium; Ana Tecic Vuger, Croatia

08:45 - 08:55 **Case 1: Detection of treatment toxicity through remote monitoring**  
Martina Pagliuca, Azienda Ospedaliera Universitaria Federico II, Napoli, Italy

08:55 - 09:10 **Mentor guided discussion**  
Nadia Harbeck, Ludwig Maximilians University - Grosshadern, Munich, Germany

09:10 - 09:20 **Case 2: Triple-negative early breast cancer in monozygotic twins**  
Marta Perachino, Genoa, Italy

09:20 - 09:35 **Mentor guided discussion**  
Ann Partridge, Dana Farber Cancer Institute, Boston, United States of America

09:35 - 09:45 **Case 3: Management of brain metastases in metastatic breast cancer treated with antibody-drug conjugates**  
Eduardo Terán Brage, University Hospital of Salamanca, Salamanca, Spain

09:45 - 10:00 **Mentor guided discussion**  
Evandro De Azambuja, Institute Jules Bordet, Brussels, Belgium

10:00 - 10:15 **Q&A and general discussion**  
All Speakers, na, Switzerland

**09:00 - 10:00** **Type: Controversy session** **Hamburg Hall**  
**Title: Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions**  
Chair(s): Peter Dubsy, Switzerland

09:00 - 09:10 **Introduction and first vote**  
Peter Dubsy, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, Switzerland

09:10 - 09:30 **Yes**  
Sabine Linn, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

09:30 - 09:50 **No**  
Joana Ribeiro, Institut Gustave Roussy, Villejuif, Cedex, France

09:50 - 10:00 **Second vote and conclusions**  
Peter Dubsy, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, Switzerland

10:15 - 10:45	<b>Type: Break</b> <b>Title: Coffee break</b>	<b>Exhibition area</b>
10:45 - 12:15	<b>Type: Educational session</b> <b>Title: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors</b> Chair(s): Sibylle Loibl, Germany; Andrew Tutt, United Kingdom	<b>Berlin Hall</b>
10:45 - 11:05	<b>Which checkpoint inhibitor, in which biomarker sub-group and when: What is approved, what is coming and what are the trials telling us</b> <u>Sibylle Loibl</u> , German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany	
11:05 - 11:25	<b>How to improve outcomes in those non-pCR after NACT+CPI</b> <u>Sheeba Irshad</u> , King's College London Guy's Hospital - NHS Foundation Trust, London, United Kingdom	
11:25 - 11:45	<b>PARP inhibition in early breast cancer: What have we learned and how can we move forward?</b> <u>Andrew Tutt</u> , ICR - Institute of Cancer Research, London, United Kingdom	
11:45 - 12:05	<b>PARP inhibitor combination strategies in early breast cancer: Rationale and results to date</b> <u>Kevin Punie</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium	
12:05 - 12:15	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	

<b>10:45 - 12:15</b>	<b>Type: Educational session</b> <b>Title: Novel endocrine therapies</b> Chair(s): Carmen Criscitiello, Italy	<b>Hamburg Hall</b>
10:45 - 11:05	<b>Clinical implementation of oral SERD: Present and future</b> <u>Carmen Criscitiello</u> , Istituto Europeo di Oncologia, Milan, Italy	
11:05 - 11:25	<b>PROTAC: Challenges and opportunity in breast cancer</b> <u>Erika Hamilton</u> , Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America	
11:25 - 11:45	<b>CERAN, SERCA: What to expect in the coming years</b> <u>Philippe Aftimos</u> , Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium	
11:45 - 12:05	<b>Impact of molecular heterogeneity on treatment selection</b> <u>Kyong Hwa Park</u> , Korea University Anam Hospital, Seoul, Korea, Republic of	
12:05 - 12:15	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	
<b>10:45 - 12:15</b>	<b>Type: Special symposium</b> <b>Title: Utility of real-world data</b> Chair(s): Peter A. Fasching, Germany; Marina Borges, Portugal	<b>Munich Hall</b>
10:45 - 11:05	<b>Real-world data: Towards achieving the achievable in cancer care</b> <u>Josee-Lyne Ethier</u> , Cancer Centre of Southeastern Ontario, Kingston, Canada	
11:05 - 11:25	<b>Quality, cost and survival: Can real-world data help to solve the equation?</b> <u>Marina Borges</u> , Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (IPO-Porto), Porto, Portugal	
11:25 - 11:45	<b>Comparative prognostic studies from real-world data: Real or not real?</b> <u>Peter A. Fasching</u> , Universitätsklinikum Erlangen, Erlangen, Germany	
11:45 - 12:05	<b>ESMO GROW: Methodological guidance for reporting oncology real-world evidence</b> <u>Suzette Delaloge</u> , Institut Gustave Roussy, Villejuif, France	
12:05 - 12:15	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	



<b>10:45 - 12:15</b>	<b>Type: Educational session</b> <b>Title: Special considerations in young breast cancer patients</b> Chair(s): Matteo Lambertini, Italy; Ann Partridge, United States of America	<b>Frankfurt Hall</b>
10:45 - 11:05	<b>Breast surgery in young women</b> <u>Viviana Galimberti</u> , IEO - Istituto Europeo di Oncologia, Milan, Italy	
11:05 - 11:25	<b>Biological peculiarities and clinical utility of genomic testing</b> <u>Ann Partridge</u> , Dana Farber Cancer Institute, Boston, United States of America	
11:25 - 11:45	<b>Optimizing adjuvant endocrine therapy</b> <u>Alexandru Eniu</u> , HRC - Hopital Riviera-Chablais - Site de Rennaz, Rennaz, Switzerland	
11:45 - 11:55	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	
11:55 - 12:15	<b>Clinical implications of germline testing: BRCA and beyond</b> <u>Shani Paluch-Shimon</u> , Hadassah University Hospital - Ein Kerem, Jerusalem, Israel	
<b>12:15 - 13:00</b>	<b>Type: Poster Display session</b> <b>Title: Poster viewing and lunch</b>	<b>Exhibition area</b>
12:15 - 12:15	<b>5P - HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment: an updated survival analysis</b> <u>Olga Martinez Saez</u> , Hospital Clinic of Barcelona, Barcelona, Spain	
12:15 - 12:15	<b>6P - Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials</b> <u>Paolo Tarantino</u> , Dana Farber Cancer Institute, Boston, United States of America	
12:15 - 12:15	<b>7P - Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer</b> <u>Esther Sanfeliu Torres</u> , Hospital Clinic of Barcelona, Barcelona, Spain	
12:15 - 12:15	<b>8P - First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer</b> <u>Olga Martinez Saez</u> , Hospital Clinic of Barcelona, Barcelona, Spain	
12:15 - 12:15	<b>9P - Prognostic Value of Baseline Neutrophil/Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer: Exploratory analysis from the CLEOPATRA trial</b> <u>Zhi Xiao</u> , Xiangya Hospital of Central South University, Changsha, China	
12:15 - 12:15	<b>10P - HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2 positive (HER2+) early breast cancer (BC)</b>	

Stefania Morganti, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America

- 12:15 - 12:15 **11P - Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the BiOnHER study**  
Bartomeu Fullana Grimalt, ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain
- 12:15 - 12:15 **12P - HER2DX in HER2-positive (HER2+) Inflammatory Breast Cancer (IBC): a correlative analysis from a phase II clinical trial**  
Adrienne Waks, Dana Farber Cancer Institute, Boston, United States of America
- 12:15 - 12:15 **13P - Analytical validation of HER2DX test for early-her2+ breast cancer**  
Esther Sanfeliu Torres, Hospital Clinic of Barcelona, Barcelona, Spain
- 12:15 - 12:15 **14P - Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status**  
François Richard, KU Leuven, Leuven, Belgium
- 12:15 - 12:15 **15P - Portraying HER2-positive breast cancer heterogeneity with spatial transcriptomics**  
Mattia Rediti, Institute Jules Bordet, Brussels, Belgium
- 12:15 - 12:15 **16P - Monitoring response to neoadjuvant chemotherapy in TNBC using circulating tumor DNA**  
Anthony Lucci, The University of Texas M. D. Anderson Cancer Center, Houston, United States of America
- 12:15 - 12:15 **17P - Prognostic and predictive non-invasive biomarkers in early Triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT)**  
Martin Nunez Abad, Hospital Universitario de la Ribera, Alzira, Spain
- 12:15 - 12:15 **18P - A translational project of the WSG-ADAPT-TN Trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological complete response (pCR) and survival after de-escalated neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC)**  
Monika Graeser, Breast Center Niederrhein, Moenchengladbach, Germany
- 12:15 - 12:15 **19P - Tumor-associated microbiome composition and response to neoadjuvant chemotherapy (NACT) in early triple negative breast cancer (TNBC)**  
Antroula Papakonstantinou, Karolinska University Hospital-Solna, Solna, Sweden
- 12:15 - 12:15 **20P - Spatial Analysis of Residual Tumor Tissue Provides New Clues for Post-Neoadjuvant Treatment Approaches in Triple Negative Breast Cancer**  
Myriam Kossai, Centre Jean PERRIN, Clermont Ferrand, France

- 12:15 - 12:15 **21P - Evaluation of breast cancer stem cell (BCSC) subpopulation and immunogenicity profile in triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy.**  
Ariadna Roqué Lloveras, ICO Girona - Institut Català d'Oncologia Girona, Girona, Spain
- 12:15 - 12:15 **22P - PD-L1 testing in mTNBC: Interplatform and interobserver reproducibility of CE-IVD assays for CPS and IC scores**  
Nicola Fusco, IEO - Istituto Europeo di Oncologia, Milan, Italy
- 12:15 - 12:15 **23P - Prognostic value of tumor infiltrating lymphocytes (TILs) and soluble immune checkpoints in early Triple negative breast cancer (TNBC)**  
Martin Nunez Abad, Hospital Universitario de la Ribera, Alzira, Spain
- 12:15 - 12:15 **24P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancer**  
Anna Karlsson, Lund University - Faculty of Medicine, Malmo, Sweden
- 12:15 - 12:15 **25P - Combining tissue microarray analysis with RNA-Sequencing to explore Platelet-derived growth factor-CC biology in primary triple-negative breast cancer**  
Sophie Lehn, Lund University - Faculty of Medicine, Lund, Sweden
- 12:15 - 12:15 **26P - ctDNA prognostic and diagnostic value for recurrence in patients with early-stage breast cancer: A systematic review and meta-analysis**  
Guilherme Nader Marta, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium
- 12:15 - 12:15 **27P - Quantitative detection of plasma extracellular vesicles in early and metastatic breast cancer patients using SiMoA technology**  
Marta Truffi, IRCCS Pavia - Istituti Clinici Scientifici Maugeri, Pavia, Italy
- 12:15 - 12:15 **28P - Rational thresholding of circulating tumor DNA copy number for early detection of disease progression in advanced metastatic breast cancer**  
Geert Martens, AZ Delta Campus Rumbeke, Roeselare, Belgium
- 12:15 - 12:15 **29P - Prevalence of high tumor mutational burden (TMB) in patients with metastatic breast cancer (mBC) assessed by liquid biopsy (LB)**  
Joana Ribeiro, Institut Gustave Roussy, Villejuif, Cedex, France
- 12:15 - 12:15 **30P - Comparison of commercially available gene expression signatures in older patients with early breast cancer**  
Alexandre De Nonneville, IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, France
- 12:15 - 12:15 **31P - C-reactive protein as a prognostic factor in early breast cancer**  
Jonas Holm, Aarhus Universitet, Aarhus, Denmark
- 12:15 - 12:15 **32P - Improvement of Diagnostic Accuracy of Breast Cancer Using Multi-protein**

**Signature Markers through Machine Learning**

Yumi Kim, CHA Gangnam Medical Center - CHA University, Seoul, Korea, Republic of

- 12:15 - 12:15 **33P - Antitumor activity of TROP2 Antibody Drug Conjugate Datopotamab Deruxtecan in Chemotherapy-Resistant Breast Cancer Models**  
Funda Meric-Bernstam, The University of Texas M. D. Anderson Cancer Center, Houston, United States of America
- 12:15 - 12:15 **34P - Investigating morphological heterogeneity in luminal breast cancer integrating artificial intelligence and spatial transcriptomics**  
Nicola Occelli, Institute Jules Bordet, Brussels, Belgium
- 12:15 - 12:15 **35P - SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive (ER+) early breast cancer (eBC) treated with aromatase inhibitors (AIs): a multicenter, prospective study**  
Benedetta Conte, IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- 12:15 - 12:15 **36P - Megestrol Acetate resistance in Estrogen Receptor Positive Advanced Breast Cancer in the MEGA trial**  
Bruno Paula, INCA - Instituto Nacional de Cancer José Alencar Gomes da Silva, Rio de Janeiro, Brazil
- 12:15 - 12:15 **37P - Enhanced tumor-immunity drives resistance to CDK4/6 inhibitors in advanced breast cancer**  
Milana Bergamino, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, Spain
- 12:15 - 12:15 **38P - Assessment of lipidomic profile in Endocrine Receptor positive (ER+) MBC patients treated with CDK 4/6 inhibitors (CDKi) and endocrine therapy (ET).**  
Alessandra Gennari, Università Degli Studi Del Piemonte Orientale Amedeo Avogadro - Scuola di Medicina, Novara, Italy
- 12:15 - 12:15 **39P - A validation study of a self-testing capillary kit, the rhelise® kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients**  
Elham Hedayati, Karolinska Institutet - Bioclinicum, Solna, Sweden
- 12:15 - 12:15 **40P - Stromal tumor infiltrating lymphocytic infiltration in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)**  
Anirudh Pabba, KU Leuven, Leuven, Belgium
- 12:15 - 12:15 **41P - Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model**  
Matthew Vandekopple, Loxo Oncology at Lilly, New York, United States of America

- 12:15 - 12:15 **42P - Conflicting results of BCL2 based on HER2 status in patients with breast cancer.**  
Airi Han, Yonsei University College of Medicine - Wonju Severance Christian Hospital, Wonju, Korea, Republic of
- 12:15 - 12:15 **43P - AKT and estrogen receptor (ER) inhibition potently impairs endocrine resistance (EndoR) in breast cancer (BC)**  
Agostina Nardone, Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, Italy
- 12:15 - 12:15 **44P - Comparison of biological characteristics in relation to survival in luminal invasive lobular vs invasive non-lobular breast carcinomas**  
Chaido Chamalidou, Skaraborgs Sjukhus Skovde, Skovde, Sweden
- 12:15 - 12:15 **45P - A three-gene signature marks the time to loco-regional recurrence in luminal-like breast cancer**  
Mara Lecchi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
- 12:15 - 12:15 **46P - PIK3CA mutation impact in prognosis of advanced HR+/HER2 negative breast cancer patients. Collaborative multicentric Argentinean real-world study (YOGA-B-01)**  
Pablo Mando, CEMIC - Centro de Educacion Medica e Investigaciones Clinicas Dr Norberto Quirno, Buenos Aires, Argentina
- 12:15 - 12:15 **47P - PIK3CA mutational status in tissue & plasma and clinicopathological features in HR+/HER2- breast cancer patients**  
Eduardo Terán Brage, University Hospital of Salamanca, Salamanca, Spain
- 12:15 - 12:15 **48P - An AI System for accurate Ki-67 IHC Assessment in Breast Cancer following the IKWG Whole Section Global Scoring Protocol**  
Ramona Erber, Universitaetsklinikum Erlangen - Pathologisches Institut, Erlangen, Germany
- 12:15 - 12:15 **49P - Metformin is associated with increased intratumoural immune infiltrates in patients with primary invasive breast cancer.**  
Constantinos Savva, University of Southampton, Southampton, United Kingdom
- 12:15 - 12:15 **50P - HER2/HER3 heterodimerization can define ER+/HER2-low breast cancer as a distinct biological entity.**  
Kristín Sigurjónsdóttir, Lund University, Lund, Sweden
- 12:15 - 12:15 **51P - Clinical and biological significance of low ERBB2 expression in ductal carcinoma in situ (DCIS) of the breast.**  
Chiara Maura Ciniselli, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
- 12:15 - 12:15 **52P - Clinical characterization of HER2 low in patients with lobular breast cancer (ILC)**

Karen Van Baelen, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium

- 12:15 - 12:15 **53P - HER2 low by immunohistochemistry (IHC) and gene expression by qRT-PCR using OncotypeDX in ER+ early breast cancer.**  
Mariangela Gaudio, Istituto Clinico Humanitas, Rozzano, Italy
- 12:15 - 12:15 **54P - Proficiency testing for HER2-low expression in breast cancer: results of the UK NEQAS ICC & ISH programme examining technical and interpretive accuracy**  
Suzanne Parry, UK NEQAS for Immunocytochemistry and In-Situ Hybridisation, London, United Kingdom
- 12:15 - 12:15 **55P - Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs. HER2 0 breast cancer (BC)**  
Francesco Schettini, IDIBAPS - August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
- 12:15 - 12:15 **56P - Association between HER2 expression level and prognosis using RT-PCR in HER2-low breast cancer**  
Saeko Nakagawa, Tokai University School of Medicine Isehara Campus, Isehara, Japan
- 12:15 - 12:15 **57P - Clinicopathologic Landscape of High Risk Early Stage HER2-Low Breast Cancer**  
Rebecca Nashed, Comprehensive Hematology-Oncology, St. Petersburg, United States of America
- 12:15 - 12:15 **58P - Quantitative indicators of TREC and KREC excision rings in breast cancer.**  
Alexander Sultanbaev, Republican Clinical Oncology Dispensary - Ufa, Ufa, Russian Federation
- 12:15 - 12:15 **59P - Tumor cells-adipocytes interactions are associated with poor disease outcome in invasive lobular carcinoma**  
Matteo Serra, Institute Jules Bordet, Brussels, Belgium
- 12:15 - 12:15 **60P - Deep learning-based digital pathology for risk stratification of atypical ductal hyperplasia/ductal carcinoma in situ**  
Chung-Yen Huang, National Taiwan University Hospital, Taipei City, Taiwan
- 12:15 - 12:15 **61P - Genomic risk and gene expression-based inference of anti-cancer drugs vulnerability in early breast cancer**  
Alexandre De Nonneville, IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, France
- 12:15 - 12:15 **62P - KI67 in ER+HER2negative pure invasive lobular breast carcinoma (ILC). What's the best Ki67 threshold to differentiate prognosis?**  
Meritxell Bellet Ezquerro, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Spain

- 12:15 - 12:15 **63P - Ki67 values and MammaPrint (MP) genomic risk in Early Breast Cancer: Correlation by ductal vs lobular histology**  
Esther Zamora, Vall d'Hebron University Hospital, Barcelona, Spain
- 12:15 - 12:15 **64P - Baseline characteristics associated with Ki67 drop after neoadjuvant endocrine therapy in patients with HR+/HER2- early breast cancer: a systematic review**  
Diogo Martins Branco, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium
- 12:15 - 12:15 **65P - Association of the Digistain Prognostic Score with outcomes in patients with HR- positive HER2-negative breast cancer**  
Hemmel Amrania, Imperial College London - South Kensington Campus, London, United Kingdom
- 12:15 - 12:15 **66P - Digital Profiling of Immune Biomarkers: Relation to Anthracycline Benefit**  
Elahe Shenasa, Vancouver Prostate Centre - UBC & VGH Centre of Excellence, Vancouver, Canada
- 12:15 - 12:15 **67P - The utility of a deep learning-based approach in HER-2/neu assessment in breast cancer**  
Semir Vranic, College of Medicine - Qatar University, Doha, Qatar
- 12:15 - 12:15 **69P - Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients**  
Muhammad Rashid, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan
- 12:15 - 12:15 **70P - Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials**  
Karen Van Baelen, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium
- 12:15 - 12:15 **71P - microRNA (miRNA) a Putative Biomarker to Better Define the Molecular Apocrine Breast Cancer (MABC) Subtype**  
Ghada Chamandi, AUB - American University of Beirut, Beirut, Lebanon
- 12:15 - 12:15 **72P - Correlation of serum cytokine patterns and clinicopathological factors in breast carcinoma patients**  
Yoel Genaro Montoyo-Pujol, Hospital General Universitario de Alicante, Alicante, Spain
- 12:15 - 12:15 **73P - Frequent discordance in PD-L1 and PD-L2 protein expression in breast cancer**  
Lubna Chaudhary, Froedtert Hospital & Medical College of Wisconsin, Milwaukee, United States of America
- 12:15 - 12:15 **74P - Transcriptomic profile identifies biological differences in very young women with breast cancer**

Iris Garrido-Cano, INCLIVA Instituto de Investigación Sanitaria, Valencia, Spain

12:15 - 12:15

**75P - Electronic patient-reported outcomes and machine learning in predicting unplanned visits and hospitalisation rates in cancer patients undergoing systemic therapy**

Andreas Trojan, University of Zurich, Zurich, Switzerland

12:15 - 12:15

**76P - Using Bioinformatics and Artificial Intelligence (AI) to Map the Cyclin-dependent Kinase 4/6 Inhibitor (CDK4/6i) Translational Biomarker Landscape**

Kim Wager, Oxford PharmaGenesis, Inc., Tubney, United Kingdom

12:15 - 12:15

**77P - BRCA mutations may induce immune-resistance in breast cancer patients treated with IO-only approach: a retrospective analysis.**

Leonardo Provenzano, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy

12:15 - 12:15

**78P - Multiplex immunohistochemistry and digital pathology analysis examining the prevalence and prognostic value of tertiary lymphoid structures in early stage hormone positive, HER2 negative breast cancer**

Mairi Lucas, Blackrock Clinic, Blackrock, Ireland

12:15 - 12:15

**79P - Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: An observational study with concurrent investigation of significance of TILs**

Fotinos-Ioannis Dimitrakopoulos, University Hospital Patras, Patras, Greece

12:15 - 12:15

**80P - Trop-2 expression and its role as a prognostic factor in patients with luminal early breast cancer**

Rafael Correa Coelho, UFRGS - Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

12:15 - 12:15

**81P - Genetic association of ABCG2 polymorphisms on triple-negative breast cancer susceptibility and prognosis**

Yeoh Ing, Universiti Sains Malaysia, George Town, Malaysia

12:15 - 12:15

**82P - Variability Of Biological Parameters Between Tumor Biopsies And Surgical Samples In Breast Cancer Patients**

Sabrina Nucera, Policlinico G. Rodolico, Catania, Italy

12:15 - 12:15

**83P - Exosomes and miRNA in Breast cancer cancerogenesis: a case-control study**

Barbara Cardinali, IRCCS Ospedale Policlinico San Martino, Genova, Italy

12:15 - 12:15

**84P - Clinicopathological features and cause-specific survival of salivary gland-like tumors of the breast**

Asmaa Ellaithy, Suez Canal University, Ismailia, Egypt



- 12:15 - 12:15 **85P - Microbiome analysis in patients with breast cancer via an oral prebiotics therapy**  
Jeongshin An, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
- 12:15 - 12:15 **86P - Phyllodes tumours: understanding more about the unknown.**  
Soomin Jang, The Royal London Hospital, London, United Kingdom
- 12:15 - 12:15 **87P - Breaking Down the Divide: An Analysis of Male Breast Cancer Demographics and Survival by Race in United States**  
Lekha Yadukumar, The Wright Center for Graduate Medical Education, Scranton, United States of America
- 12:15 - 12:15 **88P - Male Breast Cancer - A Rare Conundrum.**  
Minu Muddabhaktuni, GCRI - The Gujarat Cancer and Research Institute, Ahmedabad, India
- 12:15 - 12:15 **89P - Inclusion of racial and ethnic minorities in European Breast Cancer Clinical Trials**  
Angeliki Bania, University of Patras, Patras, Greece
- 12:15 - 12:15 **90P - Is physician-patient language concordance better for clinical trial enrollment in breast cancer patients?: A real- life study**  
Daniela Urueta Portillo, University of Texas Health Science Center San Antonio, San Antonio, United States of America
- 12:15 - 12:15 **91P - The lack of documentation of patient's body mass index (BMI) in recent clinical trials**  
Josephine Van Cauwenberge, KU Leuven - VIB Campus Gasthuisberg, Leuven, Belgium
- 12:15 - 12:15 **92P - The impact of a micro CME activity on physician knowledge and competence regarding new data in the early and metastatic breast cancer**  
Mohamed Dewji, MRD Pharma Consultancy Ltd., Chatham, United Kingdom
- 12:15 - 12:15 **97P - Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study**  
Leonor Ribeiro, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
- 12:15 - 12:15 **98P - Real-world effectiveness and safety of neratinib in the extended adjuvant treatment of patients with HER2+ early breast cancer (eBC) in the United States Community Oncology Setting**  
Diana Luftner, MHB - Brandenburg Medical School Theodor Fontane Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, Germany
- 12:15 - 12:15 **99P - Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs. trastuzumab (H) in patients with HER2-**

**positive residual invasive breast cancer after neoadjuvant treatment (NAT)**

Mark Basik, McGill University, Montreal, Canada

12:15 - 12:15

**100P - Cost-Effectiveness Analysis of Trastuzumab Emtansine as Adjuvant Treatment for Patients in Singapore with Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer**

Elaine Lim, NCCS - National Cancer Centre Singapore, Singapore, Singapore

12:15 - 12:15

**101P - Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies**

Matteo Lambertini, University of Genova - IRCCS Policlinico San Martino Hospital, Genova, Italy

12:15 - 12:15

**102P - HER2DX risk-score in early-stage HER2-positive (HER2+) breast cancer: a correlative analysis of 757 patients from the Sweden Cancerome Analysis Network - Breast (SCAN-B) dataset**

Tomas Pascual, SOLTI / Hospital Clinic of Barcelona, Barcelona, Spain

12:15 - 12:15

**103P - Impact of Prosigna test on treatment decision in lymph node negative early breast cancer- a prospective multicenter study (EMIT1)**

Hege Ohnstad, Oslo University Hospital - Ullevål Hospital, Oslo, Norway

12:15 - 12:15

**104P - Obesity and recurrence in postmenopausal, estrogen-receptor positive breast cancer patients treated with adjuvant aromatase inhibitors: a Danish population-based cohort study**

Karl Harborg, Aarhus University Hospital, Aarhus, Denmark

12:15 - 12:15

**105P - Real-world systemic treatment choices and survival outcomes of patients diagnosed with non-metastatic high-risk HR+/HER2- breast cancer in the Netherlands**

Senna Lammers, Maastricht University Medical Center (MUMC), Maastricht, Netherlands

12:15 - 12:15

**106P - Perceptions, attitudes, and behaviors towards the risk of disease recurrence among women with HER2+ early breast cancer (eBC): ASKHER2 survey French cohort analysis**

Laure Gueroult-Accolas, Patients en Réseau, Paris, France

12:15 - 12:15

**107P - Results in Chinese patients from pre-planned overall survival interim analysis in monarchE: abemaciclib plus adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer**

Zhimin Shao, Fudan University Shanghai Cancer Center, Shanghai, China

12:15 - 12:15

**108P - Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study).**

Francesca Poggio, IRCCS Ospedale Policlinico San Martino, Genova, Italy

- 12:15 - 12:15 **109P - Updated long-term overall survival of older adjuvant ibandronate-treated patients with intermediate- or high-risk early breast cancer compared with additional adjuvant capecitabine treatment - The ICE Randomized Clinical Trial**  
Valentina Nekljudova, GBG Forschungs GmbH, Neu-Isenburg, Germany
- 12:15 - 12:15 **110P - Patient preferences for adjuvant endocrine treatment of high-risk HR+/HER2- breast cancer: an adaptive choice-based conjoint analysis study from Germany**  
Achim Woeckel, UKW - University Hospital Würzburg, Würzburg, Germany
- 12:15 - 12:15 **111P - Goserelin 3 monthly depot is noninferior to Goserelin monthly depot in the treatment of Breast Cancer: A Real-World Evidence Study**  
Hao Wu, Sun Yat-sen University Cancer Center, Guangzhou, China
- 12:15 - 12:15 **112P - Correlation between HER2-negative status and risk of recurrence according to PAM50 score**  
Louise Montagnon, Centre Francois Baclesse, Caen, France
- 12:15 - 12:15 **113P - Breast-cancer recurrence after completing adjuvant endocrine therapy at 5 years.**  
Hyunyou Kim, Korea University Anam Hospital, Seoul, Korea, Republic of
- 12:15 - 12:15 **114P - Retrospective analysis to validate the CTS5 in patients from EORTC-NCIC adjuvant studies.**  
Sara Lopez-Tarruella Cobo, Hospital General Universitario Gregorio Marañón. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group, Madrid, Spain
- 12:15 - 12:15 **115P - Longterm prognostic utility of MammaPrint® (MP) by clinical and genomic risks, including Ultralow (gUL) risk patients (pts)**  
Lucia Sanz Gomez, Hospital Universitario Vall d'Hebron, Barcelona, Spain
- 12:15 - 12:15 **116P - Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC) for the treatment of HER2-positive early breast cancer (HER2 EBC): PHaTiMa**  
Santiago Gonzalez Santiago, Hospital San Pedro De Alcantara, Caceres, Spain
- 12:15 - 12:15 **117P - Age and ovarian function influence on fertility preservation attitude and outcome in breast cancer patients.**  
Gabriella Gentile, Sapienza - Università di Roma, Rome, Italy
- 12:15 - 12:15 **118P - Real world treatment patterns and clinical outcomes among high risk, early stage HER2 negative breast cancer (BC) patients in Alberta, Canada**  
Jan-Willem Henning, University of Calgary, Calgary, Canada
- 12:15 - 12:15 **119TiP - A multicenter, open-label, single-arm, non-interventional real-world study to investigate the treatment patterns of Neratinib in HER2-positive early breast cancer (EBC) in China: NER-Tree study**

Xiaojia Wang, Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, China

- 12:15 - 12:15 **120TiP - Premenopausal Women with Breast Cancer Optimally Treated with OFS (PROOFS)**  
Lotta Ada Fischer, Krankenhaus Holweide, Köln, Germany
- 12:15 - 12:15 **121TiP - LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early breast cancer at very low risk of metastasis**  
Magali Lacroix-Triki, Institut Gustave Roussy, Villejuif, France
- 12:15 - 12:15 **122TiP - Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01**  
Snehal Patel, Greenwich LifeSciences, Inc., Sugar Land, United States of America
- 12:15 - 12:15 **127P - Exploratory biomarker (BM) analyses from IMpassion050**  
Hong Zhang, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America
- 12:15 - 12:15 **128P - Long-Term Outcomes of Neoadjuvant Immunotherapy plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: an Extracted Individual Patient Data and Trial-Level Meta-Analysis**  
Mariana Gouveia, USP - Universidade de Sao Paulo, Sao Paulo, Brazil
- 12:15 - 12:15 **129P - Impact of TROP-2 and its cellular localization on prognosis of breast cancer in the GAIN cohort**  
Christina Westhoff, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, Germany
- 12:15 - 12:15 **130P - Palbociclib in combination with letrozole in HR+/HER2- residual disease after standard neoadjuvant chemotherapy: primary results of the SOLTI1710 PROMETEO II window of opportunity trial**  
Sonia Pernas Simon, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, Spain
- 12:15 - 12:15 **131P - Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer. An analysis of the Unicancer Neopal phase II study.**  
Jean-Sebastien Frenel, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France
- 12:15 - 12:15 **132P - Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer (BC)**  
Vicente Valero, The M.D. Anderson Cancer Center, Houston, United States of America
- 12:15 - 12:15 **133P - Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT) to predict response in patients (pts) with early-stage breast cancer (eBC)**

Mridula George, Rutgers Cancer Institute of New Jersey, New Brunswick, United States of America

- 12:15 - 12:15 **134P - Impact of pre-operative MammaPrint/Blueprint use for final treatment decisions in patients with Stage II/IIIa HR+/HER2- early-stage breast cancer eligible for neoadjuvant chemotherapy: the DETERMIND study.**  
Sara Liebana, Hospital Manises, Manises, Spain
- 12:15 - 12:15 **135P - Five-year survival analysis of phase II ZoNAnTax trial: Evaluation of Zoledronic-acid addition to a neoadjuvant Trastuzumab, Anthracycline and Docetaxel-containing regiment.**  
Susanne Costa, INCA - Instituto Nacional de Cancer, Rio de Janeiro, Brazil
- 12:15 - 12:15 **136P - Clinical Implications of Non-Breast Cancer Related Findings in Breast Cancer Patients Undergoing PET/CT scan prior to Neoadjuvant Systemic Therapy**  
Josefien Van Olmen, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
- 12:15 - 12:15 **137P - The Evaluation of the Effect of Inflammatory-Nutritional Prognostic Scoring (INPS) System on Treatment Response and Prognosis in Patients with Locally Advanced Breast Cancer Treated with Neoadjuvant Systemic Treatment**  
Merve Keskinilic, Dokuz Eylul University School of Medicine - Institute of Oncology, Izmir, Turkey
- 12:15 - 12:15 **138P - Activity and Efficacy of Neoadjuvant Chemotherapy (NACT) in Luminal-HER2 Negative Early Breast Cancer (EBC) according to HER2 Score (Low vs Score 0): A Retrospective Study.**  
Giovanna Garufi, Università Cattolica del Sacro Cuore, Rome, Italy
- 12:15 - 12:15 **139P - Assessing the predictive value of Systemic Inflammation Response Index (SIRI) and Systemic Immune-Inflammation Index (SII) for breast cancer patients undergoing neoadjuvant chemotherapy**  
Maryam Bagherian, Tehran University of Medical Sciences - School of Medicine, Tehran, Iran
- 12:15 - 12:15 **140P - HER2-low status and response to neoadjuvant chemotherapy and prognosis in early breast cancer**  
Tae-Kyung Yoo, Asan Medical Center - Asan Institute for Life Science, Seoul, Korea, Republic of
- 12:15 - 12:15 **141P - Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis**  
Ly Wenjie, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- 12:15 - 12:15 **142P - The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer**  
Henry Cain, Newcastle Freeman Hospital - Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

- 12:15 - 12:15 **143P - A single institution's real-world experience with the neoadjuvant Keynote-522 treatment regimen**  
Rachel Akers, Rush University Medical Center, Chicago, United States of America
- 12:15 - 12:15 **144P - TRIPLe-Negative Breast Cancer PrOSpective Registry in Middle East Africa (TRIPOLI) Study: Interim Analysis of treatment outcomes in patients who received neoadjuvant therapy**  
Hamdy Azim, Cairo Oncology Center Cairo Hospital-CairoCure, Giza, Egypt
- 12:15 - 12:15 **145P - Pathological complete response in young women with breast cancer in connection with pathogenic germline BRCA1 variants and subtype**  
Anna Hage, Charité - Universitaetsmedizin Berlin, Berlin, Germany
- 12:15 - 12:15 **146P - Updated survival analysis in NEOPERSUR trial: Neoadjuvant Pertuzumab in a real-world population in the south of Spain.**  
Alejandro Falcon Gonzalez, Hospital Universitario Virgen del Rocío, Seville, Spain
- 12:15 - 12:15 **147P - Germline BRCA Mutation Status and Response to Neoadjuvant Systemic Therapy in Breast Cancer.**  
Hyunyou Kim, Korea University Anam Hospital, Seoul, Korea, Republic of
- 12:15 - 12:15 **148P - Pattern of axillary lymph node involvement and scope of post neoadjuvant chemotherapy sentinel lymph node biopsy among breast cancer patients in developing countries.**  
Ashutosh Mishra, AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 12:15 - 12:15 **149P - HER2-low status and response to neoadjuvant chemotherapy in early breast cancer**  
Gulin Alkan, Istanbul University - Cerrahpasa Faculty of Medicine, Istanbul, Turkey
- 12:15 - 12:15 **150P - Pathological complete response after neoadjuvant chemotherapy in Her2 positive breast cancer, efficacy of biosimilar compared to Herceptin®;**  
Nassima Kouadri, CHU Ibn Rochd - Annaba, Annaba, Algeria
- 12:15 - 12:15 **151TiP - Study in progress - Pre-Operative Oncotype DX®; testing: A decision impact study (PRE-DX)**  
Grant Harris, Gateshead Health NHS Foundation Trust, Gateshead, United Kingdom
- 12:15 - 12:15 **152TiP - Trial in progress: Imatinib to convert triple negative breast cancer into estrogen receptor (ER) positive breast cancer - a window of opportunity trial**  
Barbro Linderholm, Sahlgrenska University Hospital - Jubileumskliniken, Göteborg, Sweden
- 12:15 - 12:15 **153TiP - Effects Of Resistance vs. Aerobic Training On Ki-67 And Other Health-Related Biomarkers: The Neo-Program, A Randomized Controlled Trial On Breast Cancer Patients Undergoing Neoadjuvant Treatment**

Joana Ribeiro, Institut Gustave Roussy, Villejuif, Cedex, France

- 12:15 - 12:15 **154TiP - TACTIVE-N: open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer**  
Peter A. Fasching, Universitätsklinikum Erlangen, Erlangen, Germany
- 12:15 - 12:15 **155TiP - "A randomised phase 2 trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial"**  
Ana Mafalda Antunes De Melo E Oliveira, Vall d'Hebron University Hospital, Barcelona, Spain
- 12:15 - 12:15 **156TiP - Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program)**  
Joana Ribeiro, Institut Gustave Roussy, Villejuif, Cedex, France
- 12:15 - 12:15 **157P - Comparison of Survival Outcomes in Young Patients with Breast Cancer Receiving Contralateral Prophylactic Mastectomy Versus Unilateral Mastectomy**  
Hong Bo Huang, Chongqing Medical University, Chongqing, China
- 12:15 - 12:15 **159P - The impact of the extent of the type of primary breast cancer (BC) surgery from the analysis of historical Italian trials**  
Elia Biganzoli, Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Milan, Italy
- 12:15 - 12:15 **160P - Malignant Phyllode tumor: survival outcome of different surgical approaches**  
Amr Aly, Suez Canal University Hospital, Ismailia, Egypt
- 12:15 - 12:15 **161P - DESCARTES trial: De-ESCALating RadioTherapy in patients with pathologic complete response to neoadjuvant systemic therapy**  
Annemiek Hemert, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
- 12:15 - 12:15 **162P - The Effect of radiotherapy in primary angiosarcoma of the breast (PAOB): A SEER database analysis**  
Sakhr Alshwayyat, JUST - Jordan University of Science and Technology, Irbid, Jordan
- 12:15 - 12:15 **163P - Long-term assessment of secondary malignancies (2ndM) in women with breast cancer (BC) and germline TP53 mutations (gTP53m) treated with radiation therapy (RT).**  
Tarek Ben Ahmed, Gustave Roussy - Cancer Campus, Villejuif, France
- 12:15 - 12:15 **164P - Adjuvant Radiation Therapy Amongst Immigrant and Canadian-born/Long-term Resident Women with Breast Cancer**

Ashley Eom, McMaster University, Hamilton, Canada

- 12:15 - 12:15 **165P - "Introduction of Magseed in the -DGH Setting; no Inferiority to Wire Localisation"**  
Huma Irshad, Leighton Hospital, Crewe, United Kingdom
- 12:15 - 12:15 **166P - A mono-institutional experience of field-in-field 3D-CRT planning in breast radiotherapy with FAST and FAST-forward protocols**  
Martina Camilla Daniotti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- 12:15 - 12:15 **167P - Deep learning-based whole slide image analysis to predict sentinel node status in the INSEMA cohort**  
Sibylle Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany
- 12:15 - 12:15 **168P - Preservation versus Dissection of The Intercostobrachial Nerve for Breast Cancer Surgeries: A Meta-analysis of 980 patients.**  
Miroslava Verbat, First Faculty of Medicine Charles University, Prague, Czech Republic
- 12:15 - 12:15 **169P - Hypofractionated Radiotherapy versus Conventional Radiotherapy in Postmastectomy Breast Cancer Patients: A single institution non-randomized study, prospective study**  
Richmarie Grace Uy, Jose R. Reyes Memorial Medical Center, Manila, Philippines
- 12:15 - 12:15 **170P - Comparison of the outcome between photo-medicine based dual method vs. RI method in axillary sentinel lymph node operation for breast cancer patients after neoadjuvant chemotherapy**  
Jaeyeon Woo, National Cancer Center Hospital, Goyang, Korea, Republic of
- 12:15 - 12:15 **172P - Early impact of a personalised cancer interception programme for women at non-genetic high risk of breast cancer (BC)**  
Lucie Veron, Gustave Roussy - Cancer Campus, Villejuif, France
- 12:15 - 12:15 **173P - Diet, genetic predisposition and the risk of breast cancer: a cohort study from the UK biobank**  
Pingxiu Zhu, Fujian Medical University - Qishan Campus, Fuzhou, China
- 12:15 - 12:15 **174P - Endocrine Disruptors and Life STILe in Patients Carrying BRCA Pathogenic VARIants With Breast and/or Ovarian CANcer and Women Without Neoplasm: the STILVARCA study**  
Francesco Pavese, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 12:15 - 12:15 **175P - Breast cancer in neurofibromatosis type 1: A retrospective review in the Portuguese population**  
Carolina Trabulo, Hospital Nossa Senhora do Rosário (Centro Hospitalar Barreiro Montijo, EPE), Barreiro, Portugal



- 12:15 - 12:15 **176P - Awareness & Knowledge pertaining Genetic Breast Cancer in developing countries- A Questionnaire based prospective Study of 300 Patients**  
Ashutosh Mishra, AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 12:15 - 12:15 **177P - Oncotype DX Breast Recurrence Score (ODX RS) and gBRCAm in pts with HR+/HER2-negative early breast cancer (eBC) in a retrospective cohort**  
Stefania Morganti, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
- 12:15 - 12:15 **178P - Deep learning reveals spatial disorganisation of histological features in the normal breast of breast cancer patients**  
Siyuan Chen, KCL - King's College London, London, United Kingdom
- 12:15 - 12:15 **179P - Developing the AI program for TNBC subtyping**  
Ebrucan Bulut, Uludag University - Faculty of Medicine, Bursa, Turkey
- 12:15 - 12:15 **180P - Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot.**  
Onalenna Sokwe, Jhpiego, Gaborone, Botswana
- 12:15 - 12:15 **181P - Male breast cancer (MBC): familial history (FH), clinicopathological (CP) characteristics, oncogenetic (OG) testing and outcome in a cohort of 98 patients (pts)**  
Sebastian Chretien, Centre Oscar Lambret, Lille, France
- 12:15 - 12:15 **182P - Association of non-genetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank cohort**  
Kawthar Alajmi, University of technology and applied sciences, Shinas, Oman
- 12:15 - 12:15 **183P - Clinical characteristics of early onset BRCA1-mut breast cancer with different HER2-negative molecular subtypes**  
Valeria Skachkova, State Institution N. N. Alexandrov National Cancer Centre of Belarus, Lesnoy - Minsk District, Belarus
- 12:15 - 12:15 **184P - PGS000508 as a Prediction for Breast Cancer Risk in Taiwanese Populations**  
Yi-Hsuan Lin, Taichung Veterans General Hospital, Taichung City, Taiwan
- 12:15 - 12:15 **194P - Safety outcomes by UGT1A1 status in the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2- metastatic breast cancer (mBC)**  
Peter Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, United Kingdom
- 12:15 - 12:15 **195P - Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy**  
Nadia Harbeck, Ludwig Maximilians University - Grosshadern, Munich, Germany

- 12:15 - 12:15 **196P - Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2**  
Patrick Neven, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium
- 12:15 - 12:15 **197P - ATREZZO TRIAL (SOLTI-1907) A Phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC): interim analysis**  
Tomas Pascual, SOLTI / Hospital Clinic of Barcelona, Barcelona, Spain
- 12:15 - 12:15 **198P - Relationship of diarrhea and neutropenia events with outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG): Post hoc analysis from the Phase 3 ASCENT study**  
Evandro De Azambuja, Institute Jules Bordet, Brussels, Belgium
- 12:15 - 12:15 **199P - Correlation of circulating tumor DNA (ctDNA) or Thymidine Kinase activity (TKa) Dynamic Patterns with tumor response in patients (pts) with hormone receptor (HR)+ human epidermal growth factor 2 (HER2) - advanced breast cancer (ABC) on ribociclib (RIB) + letrozole (LET) in BioItaLEE trial**  
Grazia Arpino, Università degli Studi di Napoli Federico II - Dipartimento di Farmacia, Napoli, Italy
- 12:15 - 12:15 **200P - OlympiAD: exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)**  
Elzbieta Senkus-Konefka, Medical University of Gdansk, Gdansk, Poland
- 12:15 - 12:15 **201P - Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Preliminary phase 2 results**  
Lasika Seneviratne, Los Angeles Cancer Network, Los Angeles, United States of America
- 12:15 - 12:15 **202P - A phase 1b/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) with palbociclib in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer (MBC)**  
Arlene Chan, Breast Cancer Research Centre BCRC - WA, Nedlands, Australia
- 12:15 - 12:15 **203P - Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: subgroup analysis from phase 3b LUCY trial**  
Karen Gelmon, BC Cancer Agency - Vancouver, Vancouver, Canada
- 12:15 - 12:15 **204P - Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: updated results in treatment naïve patients**  
Hope Ruqo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America

- 12:15 - 12:15 **205P - VERITAC update: phase 2 study of ARV-471, a PROteolysis Targeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer**  
Sara Hurvitz, UCLA Hematology/Oncology Santa Monica, Santa Monica, United States of America
- 12:15 - 12:15 **206P - Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2\_ advanced breast cancer (ABC): Phase 1b data from CAPItello-292**  
Patrick Neven, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium
- 12:15 - 12:15 **207P - A doublet metronomic chemotherapeutic regimen with oral vinorelbine and capecitabine (mNC) in patients with metastatic HER2-negative breast cancer: A prospective phase 2 study in China.**  
Yue Chai, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 12:15 - 12:15 **208P - Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases: a subanalysis of the German Brain metastases in Breast Cancer registry (BMBC)**  
Elena Laakmann, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany
- 12:15 - 12:15 **209P - Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: a randomized, multicenter, phase II trial (GIM12-TYPHER)**  
Martina Pagliuca, Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
- 12:15 - 12:15 **210P - Real-world outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) and germline/tumour BRCA mutations (g/tBRCA1/2m) receiving 1st-line (1L) CDK4/6i plus endocrine therapy (ET)**  
Anton Safonov, Memorial Sloan Kettering Cancer Center, New York, United States of America
- 12:15 - 12:15 **211P - ER-low breast cancer: evolution from primary tumor to relapse and prognostic impact**  
Federica Miglietta, IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy
- 12:15 - 12:15 **212P - Real world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: results from the multicenter SISTER study**  
Stefania Morganti, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
- 12:15 - 12:15 **213P - Real-World Clinical Outcomes Associated with First-Line Palbociclib and Aromatase Inhibitor Therapy Among Patients with HR+/HER2\_ Advanced Breast Cancer in Europe**  
Olga Oikonomidou, University of Edinburgh - MRC Institute of Genetics and Molecular

Medicine, Edinburgh, United Kingdom

- 12:15 - 12:15 **214P - Delphi consensus on the definition of visceral crisis in advanced breast cancer among French Breast Cancer Intergroup Unicancer (UCBG) experts**  
Rébecca Nabeth, CHU Amiens-Picardie - Site Sud, Amiens, France
- 12:15 - 12:15 **215P - Impact of Her2 Low on Survival in Patients Treated with Standard Therapies in Advanced Breast Cancer**  
Stephanie Graff, Warren Alpert Medical School of Brown University, Providence, United States of America
- 12:15 - 12:15 **216P - Sacituzumab govitecan in metastatic triple negative breast cancer: efficacy -with a focus on brain metastases- and toxicity in a real-world cohort**  
Delphine Loirat, Institut Curie, Paris, France
- 12:15 - 12:15 **217P - Incidence and outcome of brain and/or leptomeningeal metastatic disease in HER2-low breast cancer in the French ESME cohort.**  
Jean-Sebastien Frenel, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France
- 12:15 - 12:15 **218P - Characteristics and outcomes of HER2-low (H-Low) and HER2-zero (H-0) advanced breast cancer (ABC) patients (pts) from GEICAM/2014-03 (RegistEM) registry**  
Isabel Alvarez Lopez, Hospital Universitario de Donostia, San Sebastian (Donostia), Spain
- 12:15 - 12:15 **219P - Chemotherapy use and survival outcomes for patients diagnosed with metastatic hormone receptor-positive HER2-negative breast cancer, results from the Dutch SONABRE Registry**  
Sandra Geurts, Maastricht University Medical Center (MUMC), Maastricht, Netherlands
- 12:15 - 12:15 **220P - Oral Selective Estrogen Receptor Degraders for metastatic hormone receptor-positive, HER2 negative breast cancer according to ESR1 mutation: a systematic review and meta-analysis of randomized control trials.**  
Roberto Gabriel Santiago Novello, A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, Brazil
- 12:15 - 12:15 **221P - HERmione, a crossed-view survey about patients living with metastatic HER2-positive Breast Cancer**  
Laure Gueroult-Accolas, Patients en Réseau, Paris, France
- 12:15 - 12:15 **222P - Real-world clinical outcomes among patients (pts) with metastatic/advanced triple-negative breast cancer (mTNBC) in the United Kingdom (UK) and Germany (GER)**  
Peter A. Fasching, Universitätsklinikum Erlangen, Erlangen, Germany
- 12:15 - 12:15 **223P - Real-World Effectiveness of Palbociclib (Pal) Plus an Aromatase Inhibitor (AI) vs AI Alone in Patients Who Have Metastatic Breast Cancer (mBC) With**

**Lung or Liver Metastases**

Adam Brufsky, Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, United States of America

- 12:15 - 12:15 **224P - Clinical features and outcomes in HER2+ mBC patients treated with Trastuzumab deruxtecan: a subgroup analysis of the De-REAL study**  
Andrea Botticelli, AOU Sant'Andrea, Rome, Italy
- 12:15 - 12:15 **225P - Platinum-based chemotherapy and PARP Inhibitors for BRCA mutated metastatic breast cancer (LATER-BC): retrospective multicentre analysis of post-progression treatments**  
Carmine Valenza, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy
- 12:15 - 12:15 **226P - Treatment Patterns and Comorbidities in Patients With HR+/HER2- MBC: A Real-World Study in Five European Countries**  
Reshma L. Mahtani, Pfizer Inc, San Diego, United States of America
- 12:15 - 12:15 **227P - Molecular landscape of patients with early relapsed metastatic triple-negative breast cancer**  
Thomas Grinda, Institut Gustave Roussy, Villejuif, Cedex, France
- 12:15 - 12:15 **228P - The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: an exploratory analysis of the CLEOPATRA trial.**  
Guilherme Nader Marta, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium
- 12:15 - 12:15 **230P - Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: a multicenter study**  
Hasan Yildirim, Hacettepe University Oncology Hospital, Ankara, Turkey
- 12:15 - 12:15 **231P - Trastuzumab Deruxtecan for the treatment of metastatic breast cancer in the UK: real world data**  
Andy Cheng, Imperial College London - South Kensington Campus, London, United Kingdom
- 12:15 - 12:15 **232P - Real World Study of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer in the United Kingdom**  
Daire Hanna, St. Bartholomew's Hospital - Barts Health NHS Trust, London, United Kingdom
- 12:15 - 12:15 **233P - Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple negative breast cancer, results from the Dutch SONABRE Registry**  
Sandra Geurts, Maastricht University Medical Center (MUMC), Maastricht, Netherlands
- 12:15 - 12:15 **234P - Real-World Treatment Patterns and Outcomes of Patients Receiving Palbociclib Plus Endocrine Therapy in Spain: Subgroup Analysis Based on Age,**

**Sites and number of Metastatic locations, menopausal status and dose received from PALBOSPAIN Study**

Fernando Moreno Anton, Hospital Clinico Universitario San Carlos, Madrid, Spain

- 12:15 - 12:15 **236P - Trastuzumab deruxtecan in italian real-world experience: updated analysis from DE-REAL study**  
Andrea Botticelli, AOU Sant'Andrea, Rome, Italy
- 12:15 - 12:15 **237P - Real-world safety and efficacy of Trastuzumab-Deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): the TRES-Old retrospective registry**  
Giuseppe Buono, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, Italy
- 12:15 - 12:15 **238P - Real-world treatment (Tx) patterns in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)**  
Kevin Punie, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium
- 12:15 - 12:15 **239P - Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma**  
Jason Mouabbi, The University of Texas M.D. Anderson Cancer Center, Houston, United States of America
- 12:15 - 12:15 **240P - Effect of Dose Intensity (DI) of Palbociclib (PAB) and initial body weight dosage (BWD) on progression free survival (PFS): A real-world data analysis in patients with hormone-receptor (HR) positive HER2 negative metastatic breast cancer (MBC)**  
Sabela Recalde Penabad, ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain
- 12:15 - 12:15 **241P - APOBEC3-induced PIK3CA mutations predict better clinical outcomes with PI3K inhibitors in patients with PIK3CA-mutated advanced breast cancer**  
Elaria Yacoub, Cairo University, Giza, Egypt
- 12:15 - 12:15 **242P - Cyclin-dependent kinases inhibitors and dermatological reactions**  
Laura Pinto, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain
- 12:15 - 12:15 **243P - Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in metastatic breast cancer patients**  
Javier Álvarez Criado, Hospital Universitario La Paz, Madrid, Spain
- 12:15 - 12:15 **244P - Eribulin in Chinese advanced breast cancer patient intolerant to first/second-line taxane-based therapy: the patient-reported outcomes**  
Ting Luo, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China
- 12:15 - 12:15 **245P - Abemaciclib for Treating Patients with HR+, HER2- Advanced/Metastatic**

**Breast Cancer in the UK: A Real World Study**

Judy King, Royal Free Hospital NHS Foundation Trust, London, United Kingdom

12:15 - 12:15

**246P - Correlation of MIB1 Labeling Index and Hormone Receptor Status with Survival in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors and Letrozole**

Jozsef Virga, University of Debrecen - Faculty of Medicine, Debrecen, Hungary

12:15 - 12:15

**247P - Efficacy of therapy directed against PI3K and cyclin inhibitors based on the location of PI3K mutations**

Pablo Torres-Mozas, Hospital Universitario de Jaén, Jaén, Spain

12:15 - 12:15

**248P - Systemic treatment strategies following progression on CDK4/6 inhibitors in advanced breast cancer: a single-center real-world experience**

Pierluigi Di Mauro, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy

12:15 - 12:15

**249P - A retrospective review of patients receiving trastuzumab deruxtecan across five centres in Ireland with a subgroup analysis of patients with CNS involvement assessing response in the CNS**

Catherine Murphy, St. Vincents University Hospital, Dublin, Ireland

12:15 - 12:15

**250P - Liver Toxicity (LT) in patients (pts) with ER-positive HER2-negative Metastatic Breast Cancer (MBC) treated with first-line Cyclin-Dependent Kinase 4/6 inhibitors (CDKi)**

Kreina Vega Cano, Vall d'Hebron University Hospital, Barcelona, Spain

12:15 - 12:15

**251P - The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor + Endocrine Treatment**

Merve Keskinilic, Dokuz Eylul University School of Medicine - Institute of Oncology, Izmir, Turkey

12:15 - 12:15

**252P - Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 Negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study**

Seda Kahraman, Ankara Yildirim Beyazit Universty - Faculty of Medicine, Ankara, Turkey

12:15 - 12:15

**253P - Immunopheresis to Remove Soluble TNF Receptors as a Novel Immunotherapy for Patients with Advanced Breast Cancer**

Piotr Wysocki, Jagiellonian University Medical College, Krakow, Poland

12:15 - 12:15

**254P - The invasive lobular cancer of the breast (ILC): a collection of clinical and pathological data in patients with (non-)metastatic breast cancer (BC)**

Toni Ljubicic, Charité - Universitaetsmedizin Berlin, Berlin, Germany

12:15 - 12:15

**255TiP - AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic**

**breast cancer patients receiving paclitaxel, following an open-label dose optimization.**

Francois Duhoux, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, Belgium

- 12:15 - 12:15 **256TiP - TACTIVE-E: phase 1b study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer**
- Alexander Philipovskiy, Florida Cancer Specialists & Research Institute - Lake Mary Cancer Center, Lake Mary, United States of America
- 12:15 - 12:15 **257TiP - VERITAC-2: a global, randomized phase 3 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer**
- Erika Hamilton, Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America
- 12:15 - 12:15 **258TiP - A phase 2 trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): PRIMED**
- Maria Gion Cortes, Hospital Universitario Ramon y Cajal, Madrid, Spain
- 12:15 - 12:15 **259TiP - Treatment of Oligometastatic Breast Cancer (OMBC) - a randomised phase 3 trial comparing Stereotactic Ablative Radiotherapy (SABR) and systemic treatment with systemic treatment alone as first line treatment - TAORMINA**
- Barbro Linderholm, Sahlgrenska University Hospital - Jubileumskliniken, Göteborg, Sweden
- 12:15 - 12:15 **261P - The Long-term Melatonin Administration and Cancer Fatigue in Breast Cancer Patients; A Randomized, Controlled, Parallel-Group, Clinical Trial**
- Seyed Alireza Javadinia, Vasei Hospital, Sabzevar, Iran
- 12:15 - 12:15 **262P - Breast cancer survivors and healthy women: could gut microbiota make a difference? - &#8220;BiotaCancerSurvivors&#8221;; a case-control study**
- Telma Caleça, Hospital Prof. Dr Fernando Fonseca EPE (Hospital Amadora/Sintra), Amadora, Portugal
- 12:15 - 12:15 **263P - Cross-sectional nationwide population-based study of living conditions, and identification of sexual and fertility profiles among young women after breast cancer in France: a study of the French Network of Cancer Registries (FRANCIM)**
- Emerline Assogba, Centre Georges-François Leclerc (Dijon), Dijon, France
- 12:15 - 12:15 **264P - Impact of a cardio-oncology rehabilitation framework among high cardiovascular risk breast cancer survivors**
- Helena Guedes, CHVNG/E - Centro Hospitalar de Vila Nova de Gaia/Espinho - Unidade 1



- EPE-SNS, Vila Nova de Gaia, Portugal

- 12:15 - 12:15 **265P - UCATS: A national specialist service for integration of gender affirming and oncological care in transgender patients with breast cancer**  
Alison Berner, Cancer Research UK Barts Centre - Queen Mary University of London, London, United Kingdom
- 12:15 - 12:15 **267P - Ultrasound-Guided Injection With or Without Rehabilitation Exercise in Breast Cancer Survivors with Subacromial-Deltoid Bursitis: Long-Term Results of a Pilot Randomized Clinical Study**  
Arianna Folli, University of Eastern Piedmont "A. Avogadro", Novara, Italy
- 12:15 - 12:15 **268P - Effects of Aroma Lymphatic Tressage on Lower Extremity Edema by Taxane-based Chemotherapy and Quality of Life in Patients with Breast Cancer**  
Yangsun Ha, CHA University, Seongnam, Korea, Republic of
- 12:15 - 12:15 **269P - Treatment for vasomotor symptoms in women on adjuvant endocrine therapy after breast cancer: real-world findings from the REALISE study**  
Mia Harvey, Adelphi Real World - Adelphi Group, Bollington, United Kingdom
- 12:15 - 12:15 **270P - Real-world data of cardiac disorders screening in breast cancer survivors.**  
Alaeddine Saidi, CHU Tlemcen - Centre Hospitalo-Universitaire Dr Tidjani Damerdji, Tlemcen, Algeria
- 12:15 - 12:15 **271P - Impact of COVID-19 vaccination on health-related quality of life in patients with breast cancer**  
Marie Forster, LMU - Ludwig Maximilians University of Munich, Munich, Germany
- 12:15 - 12:15 **272P - Competitive cause of death in Elderly breast cancer survivors**  
Juan Sanchez, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain
- 12:15 - 12:15 **273P - Effect of adjuvant chemotherapy on sarcopenia in early breast cancer patients**  
Sang Yull Kang, Chonbuk National University Hospital, Jeonju, Korea, Republic of
- 12:15 - 12:15 **274P - Racial and ethnic disparities in breast cancer mortality in women with and without diabetes between 2005 and 2020**  
Anas Al Zubaidi, Johns Hopkins University School of Medicine, Boston, United States of America
- 12:15 - 12:15 **275P - Serological response to COVID-19 vaccine in patients with advanced breast cancer**  
Pablo Casado Cuesta, Hospital Universitario de Basurto, Bilbao, Spain
- 12:15 - 12:15 **276P - Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis**

Luca Arecco, IRCCS Ospedale Policlinico San Martino, Genova, Italy

12:15 - 12:15 **277TiP - OASIS 4 study design: a Phase 3 trial assessing the efficacy and safety of elinzanetant in the treatment of vasomotor symptoms caused by adjuvant endocrine therapy for breast cancer**

Fatima Cardoso, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, Portugal

**12:30 - 13:30** **Type: Industry Satellite Symposium** **Hamburg Hall**  
**Title: MSD - Multi-disciplinary management of early TNBC to improve outcomes**  
Chair(s): Thorsten Kuehn, Germany

12:30 - 12:35 **Introduction and objectives**

Thorsten Kuehn, University of Ulm, Ulm, Germany

12:35 - 12:50 **The medical oncologist's perspective**

Rupert Bartsch, Medical University of Vienna, Vienna, Austria

12:50 - 13:05 **The surgeon's perspective**

Sherko Kuemmel, KEM, Evang. Hospital Essen-Mitte, Essen, Germany

13:05 - 13:20 **Case discussions**

Thorsten Kuehn, University of Ulm, Ulm, Germany

13:20 - 13:30 **Q&A**

To Be Announced, Barcelona, Spain

- |                      |  |                    |
|----------------------|--|--------------------|
| <b>12:30 - 13:30</b> | <p><b>Type: Industry Satellite Symposium</b></p> <p><b>Title: Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer</b></p> <p>Chair(s): Wolfgang Janni, Germany</p> | <b>Munich Hall</b> |
| 12:30 - 12:40        | <p><b>Welcome and introduction - Treatment landscape and emerging needs in metastatic breast cancer: Where are we today?</b></p> <p><u>Wolfgang Janni</u>, Ulm Medical University, Ulm, Germany</p>  |                    |
| 12:40 - 13:10        | <p><b>Optimal management in mTNBC: What have we learned from clinical practice?</b></p> <p><u>Ana Mafalda Antunes De Melo E Oliveira</u>, Vall d'Hebron University Hospital, Barcelona, Spain</p>  |                    |
| 13:10 - 13:30        | <p><b>A new era of treatment for HR+/HER2- mBC: What do the clinical data tell us?</b></p> <p><u>Komal Jhaveri</u>, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, United States of America</p>  |                    |
| 13:30 - 13:30        | <p><b>Closing remarks</b></p> <p><u>Wolfgang Janni</u>, Ulm Medical University, Ulm, Germany</p>   |                    |

<b>12:30 - 13:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Daiichi Sankyo   AstraZeneca - Unfolding the HER2 spectrum together: An interactive discussion</b> Chair(s): Peter Schmid, United Kingdom	<b>Frankfurt Hall</b>
12:30 - 12:35	<b>Welcome and introductions</b> Peter Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, United Kingdom	
12:35 - 12:45	<b>Opening up the options in HER2-targeted treatment</b> Shanu Modi, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America	
12:45 - 13:00	<b>Broadening the HER2 spectrum: Targeting 3+, 2+, 1+, 0</b> Paolo Tarantino, Dana Farber Cancer Institute, Boston, United States of America	
13:00 - 13:15	<b>Expanding the HER2 spectrum: Targeting earlier stage disease</b> Javier Cortes, International Breast Cancer Center (IBCC); Pangaea Oncology, Quironsalud Group Madrid & Barcelona, Madrid and Barcelona, Spain	
13:15 - 13:25	<b>Q&amp;A / discussion</b> To Be Announced, Barcelona, Spain	
13:25 - 13:30	<b>Close</b> Peter Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, United Kingdom	
<b>13:15 - 14:00</b>	<b>Type: Young Oncologists session</b> <b>Title: Meet your mentor: Looking for international fellowships and educational/research opportunities in breast cancer</b> Chair(s): Rodrigo Sanchez Bayona, Spain; Kevin Punie, Belgium; Ana Tecic Vuger, Croatia	<b>Exhibition area</b>
13:15 - 13:15	<b>Mentor</b> Evandro De Azambuja, Institute Jules Bordet, Brussels, Belgium	
13:15 - 13:15	<b>Mentor</b> Nadia Harbeck, Ludwig Maximilians University - Grosshadern, Munich, Germany	
13:15 - 13:15	<b>Mentor</b> Fabrice André, Gustave Roussy - Cancer Campus, Villejuif, France	

<b>14:00 - 14:30</b>	<b>Type: Keynote lecture</b> <b>Title: Keynote lecture -The future of early cancer detection</b> Chair(s): Suzette Delaloge, France	<b>Berlin Hall</b>
14:00 - 14:05	<b>Introduction by the Chair</b> <u>Suzette Delaloge</u> , Institut Gustave Roussy, Villejuif, France	
14:05 - 14:30	<b>The future of early cancer detection</b> <u>David Crosby</u> , Cancer Research UK, London, United Kingdom	
<b>14:45 - 16:15</b>	<b>Type: Educational session</b> <b>Title: New algorithms for HER2 positive breast cancer</b> Chair(s): Giuseppe Curigliano, Italy; Hiroji Iwata, Japan	<b>Berlin Hall</b>
14:45 - 15:05	<b>New algorithm for HER2 positive eBC</b> <u>Giuseppe Curigliano</u> , Istituto Europeo di Oncologia, Milan, Italy	
15:05 - 15:25	<b>New algorithm for HER2 positive mBC</b> <u>Shanu Modi</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America	
15:25 - 15:45	<b>New algorithm for HER2 positive mBC with brain mets</b> <u>Thomas Bachelot</u> , Centre Léon Bérard, Lyon, France	
15:45 - 16:05	<b>New algorithm for HER2 positive mBC obtained complete clinical response (cCR)</b> <u>Hiroji Iwata</u> , Aichi Cancer Center Hospital, Nagoya, Japan	
16:05 - 16:15	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	

**14:45 - 16:15** **Type: Multidisciplinary Tumour Board** **Hamburg Hall**  
**Title: Post neoadjuvant local treatment in 2023**  
Chair(s): Paolo Tarantino, United States of America; Peter Dubsy, Switzerland

14:45 - 15:05 **Indications and impact of pre-post treatment imaging**  
Fiona Gilbert, University of Cambridge, Cambridge, United Kingdom

15:05 - 15:25 **Influence of new treatments on surgical decisions**  
Peter Dubsy, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, Switzerland

15:25 - 15:45 **Post adjuvant radiation therapy: What changes**  
Boon Chua, Prince of Wales Hospital - Nelune Comprehensive Cancer Centre, Sydney, Australia

15:45 - 16:05 **Medical oncologist's point of view**  
Paolo Tarantino, Dana Farber Cancer Institute, Boston, United States of America

16:05 - 16:15 **Q&A and discussion**  
To Be Announced, Barcelona, Spain

**14:45 - 16:15** **Type: Special symposium** **Munich Hall**  
**Title: ctDNA monitoring in early and advanced breast cancer**  
Chair(s): Marleen Kok, Netherlands; Nicholas Turner, United Kingdom

14:45 - 15:05 **ctDNA clearance during neoadjuvant treatment of breast cancer**  
Marija Balic, Medical University of Graz, Graz, Austria

15:05 - 15:25 **ctDNA tracking in adjuvant setting for TNBC: Lessons from c-TRAK trial**  
Nicholas Turner, Oncomedica S.A., London, United Kingdom

15:25 - 15:45 **ctDNA for decision making in the metastatic setting: Lessons from the PADA-1 trial**  
François Clément Bidard, Institut Curie, Paris, France

15:45 - 16:05 **ctDNA dynamics during immune checkpoint inhibition**  
Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands

16:05 - 16:15 **Q&A and discussion**  
To Be Announced, Barcelona, Spain

<b>14:45 - 16:00</b>	<b>Type: Special session</b> <b>Title: Bringing the patient voice to cancer research (GRASP session)</b> Chair(s): Julia Maues, United States of America	<b>Frankfurt Hall</b>
14:45 - 14:45	<b>Welcome and introduction</b> <u>Julia Maues</u> , GRASP, Washington, United States of America	
14:45 - 15:00	<b>How GRASP is driving bidirectional learning between cancer patients and researchers</b> <u>Christine Hodgdon</u> , GRASP - Guiding Researches and Advocates to Scientific Partnerships, Baltimore, United States of America	
15:00 - 15:15	<b>Formation of the Lobular Breast Cancer Alliance and Pittsburgh's rapid autopsy programme in coordination with patient advocates</b> <u>Steffi Oesterreich</u> , Magee Womens Research Institute, Pittsburgh, United States of America	
15:15 - 15:30	<b>Adding the patient voice to science: The impact on research</b> <u>Aleix Prat</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, Spain	
15:30 - 15:45	<b>HOPE: The first patient-led study for the genomic analysis of mBC</b> <u>Rosa Olmos</u> , Vidaria Centro Médico, Barcelona, Spain	
15:45 - 16:00	<b>Conclusions and clinical perspectives</b> <u>To Be Announced</u> , Barcelona, Spain	
<b>16:15 - 16:45</b>	<b>Type: Break</b> <b>Title: Coffee break</b>	<b>Exhibition area</b>

<b>16:45 - 18:15</b>	<b>Type: Proffered Paper session</b> <b>Title: Proffered Paper session 2: Best abstracts</b> Chair(s): Suzette Delalogue, France; Erika Hamilton, United States of America	<b>Berlin Hall</b>
16:45 - 16:57	<b>1240 - Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial</b> <u>Ana Mafalda Antunes De Melo E Oliveira</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
16:57 - 17:09	<b>1890 - A phase 2 Study of Patritumab Deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)</b> <u>Barbara Pistilli</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
17:09 - 17:19	<b>Invited Discussant 1240 and 1890</b> <u>Rebecca Dent</u> , NCCS - National Cancer Centre Singapore, Singapore, Singapore	
17:19 - 17:29	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	
17:29 - 17:41	<b>LBA1 - Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)</b> <u>Carlos Barrios</u> , Hospital São Lucas, PUCRS, Porto Alegre, Brazil	
17:41 - 17:53	<b>1230 - Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABC SG-52 / ATHENE)</b> <u>Gabriel Rinnerthaler</u> , Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria	
17:53 - 18:03	<b>Invited Discussant LBA1 and 1230</b> <u>Matteo Lambertini</u> , University of Genova - IRCCS Policlinico San Martino Hospital, Genova, Italy	
18:03 - 18:13	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	



18:15 - 19:00	<b>Type: Young Oncologists session</b> <b>Title: Vesalius talk: Navigating through different career options as a breast oncologist</b>	<b>Exhibition area</b>
	Chair(s): Rodrigo Sanchez Bayona, Spain; Kevin Punie, Belgium; Matteo Lambertini, Italy; Ana Tecic Vuger, Croatia	
18:15 - 18:15	<b>Panellist</b> <u>Erika Hamilton</u> , Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America	
18:15 - 18:15	<b>Panellist</b> <u>Vaz Luis Ines</u> , Institut Gustave Roussy, Villejuif, France	
18:15 - 18:15	<b>Panellist</b> <u>Alex Prat</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, Spain	
18:30 - 19:30	<b>Type: Industry Satellite Symposium</b> <b>Title: Pfizer - Guiding light: Practical perspectives of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer</b>	<b>Hamburg Hall</b>
	Chair(s): Marc Thill, Germany	
18:30 - 18:35	<b>Welcome</b> <u>Marc Thill</u> , Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, Germany	
18:35 - 18:50	<b>Navigating through clinical trial- and real world-based evidence</b> <u>Richard Finn</u> , UCLA - David Geffen School of Medicine, Los Angeles, United States of America	
18:50 - 19:05	<b>Aiming for smooth sailing</b> <u>Marc Thill</u> , Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, Germany	
19:05 - 19:15	<b>The patient as the North Star</b> <u>Grazia Arpino</u> , Università degli Studi di Napoli Federico II - Dipartimento di Farmacia, Napoli, Italy	
19:15 - 19:25	<b>Panel discussion with Q&amp;A</b> <u>To Be Announced</u> , Barcelona, Spain	
19:25 - 19:30	<b>Meeting close</b> <u>Marc Thill</u> , Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, Germany	

**18:30 - 19:30** **Type: Industry Satellite Symposium** **Munich Hall**  
**Title: F. Hoffmann-La Roche - PI3King the right treatment for every patient with HR+ breast cancer**  
 Chair(s): Sibylle Loibl, Germany

18:30 - 18:35 **Introduction**  
Sibylle Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany

18:35 - 18:55 **PI3K: A challenge to target but unmet need drives us onwards to success**  
Dejan Juric, MGH - Massachusetts General Hospital, Boston, United States of America

18:55 - 19:15 **PI3Kis: The clinical story so far and the next chapter**  
Sibylle Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany

19:15 - 19:30 **Q&A / discussion**  
To Be Announced, Barcelona, Spain

**18:30 - 19:30** **Type: Industry Satellite Symposium** **Frankfurt Hall**  
**Title: Seagen - Case by case: How to optimize HER2+ metastatic breast cancer (MBC) treatment in second line and beyond**  
 Chair(s): Andreas Schneeweiss, Germany

18:30 - 18:35 **Welcome and introductions**  
Andreas Schneeweiss, German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, Germany

18:35 - 18:45 **Evolving treatment landscape**  
Andreas Schneeweiss, German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, Germany

18:45 - 19:05 **Progression after T-DXd: What to do in 3L? (case-based discussion)**  
Joyce O'Shaughnessy, Texas Oncology, Dallas, United States of America

19:05 - 19:25 **Optimizing outcomes for patients with CNS relapse (case-based discussion)**  
Barbara Pistilli, Institut Gustave Roussy, Villejuif, Cedex, France

19:25 - 19:30 **Q&A / Key takeaways**  
To Be Announced, Barcelona, Spain

13.05.2023

08:45 - 10:15	<p><b>Type: Educational session</b>  <b>Title: Precision/personalised breast cancer medicine: Where do we stand</b>          Chair(s): Christine Desmedt, Belgium</p>	<b>Berlin Hall</b>
08:45 - 09:05	<p><b>Lessons learned from large omics-based screening programmes</b>  <u>Fabrice André</u>, Gustave Roussy - Cancer Campus, Villejuif, France</p>	
09:05 - 09:25	<p><b>Tissue or liquid: Assessing your marker of interest</b>  <u>Jisun Kim</u>, Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of</p>	
09:25 - 09:45	<p><b>Refining diagnosis and treatment of lobular breast cancer</b>  <u>Steffi Oesterreich</u>, Magee Womens Research Institute, Pittsburgh, United States of America</p>	
09:45 - 10:05	<p><b>Adjusting treatment to patient adiposity</b>  <u>Christine Desmedt</u>, KU Leuven - VIB Campus Gasthuisberg, Leuven, Belgium</p>	
10:05 - 10:15	<p><b>Q&amp;A and discussion</b>  <u>To Be Announced</u>, Barcelona, Spain</p>	

<b>08:45 - 10:15</b>	<b>Type: Educational session</b> <b>Title: Beyond breast cancer: Survivorship</b> Chair(s): Patricia Ganz, United States of America; Laure Gueroult-Accolas, France	<b>Frankfurt Hall</b>
08:45 - 09:05	<b>Cope with the transition: Setting up a post-cancer consultation</b> <u>Patricia Ganz</u> , Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, United States of America	
09:05 - 09:25	<b>Back to work: What oncologists need to know and how they could help</b> <u>Agnes Dumas</u> , Inserm, Inserm, Pôle de Recherche Clinique, Paris, France	
09:25 - 09:45	<b>Intimate life and sexuality: Anticipate, inform and provide evidence-based guidance</b> <u>Luzia Travado</u> , Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, Portugal	
09:45 - 10:05	<b>Survivor and metavivor: The role of patient organizations in accompanying the long term healing process</b> <u>Laure Gueroult-Accolas</u> , Patients en Réseau, Paris, France	
10:05 - 10:15	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	
<b>09:00 - 09:50</b>	<b>Type: Special session</b> <b>Title: Omitting anthracyclines for the adjuvant treatment of early breast cancer: The case of TNBC</b> Chair(s): Suzette Delalogue, France; Peter A. Fasching, Germany	<b>Hamburg Hall</b>
09:00 - 09:05	<b>Introduction to the topic</b> <u>Peter A. Fasching</u> , Universitätsklinikum Erlangen, Erlangen, Germany	
09:05 - 09:10	<b>96MO - Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer (TNBC): a non-inferiority meta-analysis</b> <u>Fabio Girardi</u> , IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy	
09:10 - 09:25	<b>Statistician's perspective</b> <u>Richard Gray</u> , University of Oxford, Oxford, United Kingdom	
09:25 - 09:40	<b>Clinician's perspective</b> <u>Peter A. Fasching</u> , Universitätsklinikum Erlangen, Erlangen, Germany	
09:40 - 09:50	<b>Q&amp;A and discussion</b> <u>To Be Announced</u> , Barcelona, Spain	

<b>10:15 - 10:45</b>	<b>Type: Break</b> <b>Title: Coffee break</b>	<b>Exhibition area</b>
<b>10:45 - 12:15</b>	<b>Type: Meeting highlights</b> <b>Title: ESMO Breast 2023 key takeaways</b> Chair(s): Erika Hamilton, United States of America; Giuseppe Curigliano, Italy	<b>Berlin Hall</b>

- 10:45 - 11:05    **Translational research**  
Christine Desmedt, KU Leuven - VIB Campus Gasthuisberg, Leuven, Belgium
- 11:05 - 11:25    **Early breast cancer**  
Sung-Bae Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of
- 11:25 - 11:45    **Metastatic breast cancer**  
Erika Hamilton, Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America
- 11:45 - 12:05    **Supportive care**  
Vaz Luis Ines, Institut Gustave Roussy, Villejuif, France
- 12:05 - 12:15    **Closure of the meeting**  
Erika Hamilton, Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America

<b>10:45 - 12:15</b>	<b>Type: Special session</b> <b>Title: Patient advocacy (Patient Advocates Working Group session)</b> Chair(s): Tanja Spanic, Slovenia	<b>Frankfurt Hall</b>
10:45 - 11:05	<b>European guidelines on breast cancer screening and diagnosis</b> <u>Gian Paolo Morgano</u> , European Commission – Joint Research Centre, Ispra, Italy	
11:05 - 11:25	<b>Evaluation and optimisation of breast cancer screening programmes: Through the lens of Europe</b> <u>Nadine Zielonke</u> , Erasmus MC, Rotterdam, Netherlands	
11:25 - 11:45	<b>Which screening method is suggested for women under 50 years and for those over 74 years of age</b> <u>Alexandra Athanasiou</u> , Mitera Hospital, Marousi, Greece	
11:45 - 12:05	<b>National screening programmes: Patient advocate perspective</b> <u>Tanja Spanic</u> , Europa Donna Slovenia, Ljubljana, Slovenia	
12:05 - 12:15	<b>Q&amp;A and discussion</b>	
<b>12:15 - 13:00</b>	<b>Type: Young Oncologists session</b> <b>Title: Meet your mentor: Hurdles to overcome when starting your breast cancer research lab</b> Chair(s): Kevin Punie, Belgium; Ana Tecic Vuger, Croatia	<b>Exhibition area</b>
12:15 - 12:15	<b>Mentor</b> <u>Monica Arnedos</u> , Institute Bergonié, Bordeaux, France	
12:15 - 12:15	<b>Mentor</b> <u>Marleen Kok</u> , Netherlands Cancer Institute, Amsterdam, Netherlands	
12:15 - 12:15	<b>Mentor</b> <u>Christine Desmedt</u> , KU Leuven - VIB Campus Gasthuisberg, Leuven, Belgium	

<b>12:30 - 13:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Daiichi Sankyo   AstraZeneca - HER2 treat: Discussing challenging breast cancer cases - An interdisciplinary and interactive approach</b> Chair(s): Peter A. Fasching, Germany	<b>Hamburg Hall</b>
12:30 - 12:40	<b>Welcome and introduction</b> <u>Peter A. Fasching</u> , Universitätsklinikum Erlangen, Erlangen, Germany	
12:40 - 12:50	<b>Patient case 1: The importance of accurately identifying HER2 status</b>  <u>Magali Lacroix-Triki</u> , Institut Gustave Roussy, Villejuif, France	
12:50 - 13:00	<b>Patient case 2: Treatment options for patients with HER2-low expressing tumours</b> <u>Peter A. Fasching</u> , Universitätsklinikum Erlangen, Erlangen, Germany	
13:00 - 13:10	<b>Patient case 3: Optimising adverse events management in HER2+ metastatic breast cancer</b> <u>Cristina Saura Manich</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
13:10 - 13:25	<b>Panel discussion and Q&amp;A</b> <u>To Be Announced</u> , Barcelona, Spain	
13:25 - 13:30	<b>Closing remarks</b> <u>Peter A. Fasching</u> , Universitätsklinikum Erlangen, Erlangen, Germany	
<b>13:30 - 14:00</b>	<b>Type: Break</b> <b>Title: Lunch&amp;go</b>	<b>Exhibition area</b>